<?xml version="1.0" encoding="UTF-8"?>
<p id="Par32">β-D-N
 <sup>4</sup>-Hydroxycytidine (NHC/EIDD-2801) is an oral ribonucleoside analogue against various RNA viruses (including influenza, Ebola, CoV and Venezuelan Equine Encephalitis Virus (VEEV)) has broad-spectrum antiviral activity [
 <xref ref-type="bibr" rid="CR74">74</xref>–
 <xref ref-type="bibr" rid="CR76">76</xref>]. A study showed that the mice infected with COVID-19 or MERS-CoV, prophylactic and therapeutic administration of NHC/EIDD-2801 can improve lung function and reduce viral titer and weight loss [
 <xref ref-type="bibr" rid="CR77">77</xref>]. The efficacy and oral bioavailability of NHC/EIDD-2801 against a variety of coronaviruses highlight their potential utility as effective antiviral agents against COVID-19 and other future zoonotic coronaviruses.
</p>
